- Home
- LSB vs UDR Comparison
LSB vs UDR Comparison
Compare LSB & UDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- UDR
- Stock Information
- Founded
- LSB 2002
- UDR 1972
- Country
- LSB China
- UDR United States
- Employees
- LSB N/A
- UDR N/A
- Industry
- LSB
- UDR Real Estate Investment Trusts
- Sector
- LSB
- UDR Real Estate
- Exchange
- LSB NYSE
- UDR Nasdaq
- Market Cap
- LSB 49.8M
- UDR 14.6B
- IPO Year
- LSB N/A
- UDR N/A
- Fundamental
- Price
- LSB $3.44
- UDR $42.79
- Analyst Decision
- LSB
- UDR Buy
- Analyst Count
- LSB 0
- UDR 18
- Target Price
- LSB N/A
- UDR $44.56
- AVG Volume (30 Days)
- LSB 23.5K
- UDR 1.7M
- Earning Date
- LSB 01-21-2025
- UDR 02-04-2025
- Dividend Yield
- LSB N/A
- UDR 3.92%
- EPS Growth
- LSB N/A
- UDR N/A
- EPS
- LSB N/A
- UDR 0.37
- Revenue
- LSB $79,415,311.00
- UDR $1,677,719,000.00
- Revenue This Year
- LSB $39.33
- UDR N/A
- Revenue Next Year
- LSB $75.61
- UDR $0.89
- P/E Ratio
- LSB N/A
- UDR $116.33
- Revenue Growth
- LSB N/A
- UDR 0.06
- 52 Week Low
- LSB $1.88
- UDR $34.19
- 52 Week High
- LSB $11.20
- UDR $47.55
- Technical
- Relative Strength Index (RSI)
- LSB 58.78
- UDR 38.89
- Support Level
- LSB $2.10
- UDR $42.33
- Resistance Level
- LSB $3.70
- UDR $44.02
- Average True Range (ATR)
- LSB 0.39
- UDR 0.83
- MACD
- LSB 0.10
- UDR -0.13
- Stochastic Oscillator
- LSB 73.93
- UDR 15.41
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About UDR UDR Inc.
UDR Inc is a real estate investment trust that owns, operates, acquires, renovates, develops, redevelops, disposes of, and manages multifamily apartment communities in targeted markets located in the United States. The company has two reportable segments; Same-Store Communities segment represents those communities acquired, developed, and stabilized prior to January 1, 2021, and held as of December 31, 2022, and Non-Mature Communities/Other segment represents those communities that do not meet the criteria to be included in Same-Store Communities, including, but not limited to, recently acquired, developed and redeveloped communities, and the non-apartment components of mixed-use properties. It generates key revenue from Same-Store Communities.